Although the dose of some drugs is commonly adjusted for weight, weight-related dosage adjustments are rarely made for most antimicrobials. We reviewed the English-language literature on antimicrobial pharmacokinetics and dosing in obesity. Although there are many potential pharmacokinetic consequences of obesity, the actual effect on the pharmacokinetics and clinical efficacy of most antimicrobials is unknown. Since Ç30% of adipose is water, an empirical approach is use of the Devine formula to calculate ideal body weight (IBW), to which is added a dosing weight correction factor (DWCF) of 0. Body surface area (BSA) is used as the basis for calculating cancer chemotherapy doses, and some researchers have advocated the use of BSA to calculate antimicrobial dose [15 -17].
chemotherapeutic agents, anesthetics, and more recently heparin [1 -9] -is commonly adjusted for weight, weight-related Equations to calculate IBWs for men and women are given dosage adjustments for antimicrobials are rarely made. Distriin table 2 (curiously, the equations mix metric and standard bution, metabolism, and clearance of many drugs are altered measures) [10 -12] . The commonly used Devine formula [10] by physiological changes associated with obesity (table 1) .
defines IBW for men as 50 kg plus 2.3 times the height in Are antimicrobial pharmacokinetics altered in obese patients? inches over 60 inches; for women, a base weight of 45 kg is Should their antimicrobial dose be increased? If so, should the used instead. While there are only a handful of definitions of adjustment be based on actual body weight (ABW) or on a IBW [10 -13] , there are many definitions of obesity [8, 14] ; percentage of ABW? After treating several patients who one frequently used definition is body fat contents of 25% weighed 200% or more of their ideal body weights (IBWs), and §30% of ABW for men and women, respectively [8] . A we reviewed the English-language literature for information on common definition of morbid or extreme obesity is weight antimicrobial pharmacokinetics and dosing in obesity in an exceeding 200% of IBW [8] . attempt to optimize antimicrobial management.
Body surface area (BSA) is used as the basis for calculating cancer chemotherapy doses, and some researchers have advocated the use of BSA to calculate antimicrobial dose [15 -17] .
Methods
One study showed that the standard formula for calculating We used three computerized MEDLINE search programs BSA in lean subjects [18] still applies for extremely obese (Silver Platter, OVID, and Grateful Med) and the International subjects [19] . However, with the exception of calculating Pharmaceutical Abstracts to identify articles in the Englishacyclovir doses for children, BSA is not used in antimicrobial language literature from 1966 to 1996, using specific antimicrodosing, and no studies have demonstrated that use of BSA bial names and the subject headings and key words pharmacooptimally predicts serum antimicrobial levels in obese subjects kinetics, obesity, and morbid obesity as cross-references. We [20] . also retrieved references cited in articles identified by the comBody mass index, the weight in kilograms divided by height puter search and in pharmacokinetics textbooks.
in meters squared, has also been advocated as a basis for calculating drug dosage, but a study by Traynor et al.
[21] demonstrated that using IBW as the basis for calculating aminoglycoside dosing was as accurate as using body mass index. assessed DWCFs. The disposition of drugs in obesity is studied with use of Drugs bind to three major serum proteins: albumin, a 1 -acid several animal models, including the genetically obese (Zucker) glycoprotein, and lipoproteins [8] . Since bound drug is generrat and the overfed (Sprague-Dawley) rat. Of these two, the ally unavailable for hepatic extraction, for metabolism, and overfed rat more closely models the changes in body composifor renal excretion, increased protein binding may result in tion and organ function that occur in obese humans [22, 23] .
decreased metabolism or clearance. Most antimicrobials bind Animal models have been used to study antimicrobial disposito albumin [36] ; albumin levels are not altered in obesity [37] . tion [24 -30] .
The levels of a 1 -acid glycoprotein may increase in morbid obesity [27] . Morita and Yamaji [38] noted a significant positive correlation between protein binding of vancomycin and levels of a 1 -acid glycoprotein.
Pharmacokinetic Considerations Specific to Obesity
Obese people also have increased levels of lipoproteins, triglycerides, cholesterol, and free fatty acids [7, 8, 39, 40] , which Obesity causes many physiological changes, some of which bind to serum proteins such as albumin, inhibiting protein bindmay negate the pharmacokinetic consequences of others; the ing of drugs. In vitro studies by Suh et al. [41] found that high net pharmacological significance is uncertain. There are four levels of free fatty acids significantly decreased the protein general considerations in evaluating pharmacokinetics in obebinding of cefamandole, dicloxacillin, and sulfamethoxazole sity: absorption, distribution, metabolism, and elimination. It and increased protein binding of benzylpenicillin, cephalothin, is not known if absorption, whether from oral or intramuscular and cefoxitin. Amphotericin circulates bound to lipoproteins sites, is changed by obesity. Although hemodynamic studies as well as other proteins [42] . performed by Alexander et al. [31] found that, compared with Koldin et al. [30] studied the toxicity of amphotericin B in lean controls, obese subjects had a greater splanchnic blood hypercholesterolemic rabbits vs. normal rabbits and concluded flow, there is no evidence that the oral absorption of drugs is that there was no difference in toxicity. Amphotericin is less increased in obesity. A report by Cockshott et al. showed that toxic to pig kidney cells when associated with high-density most ''intramuscular'' injections are actually ''intralipomalipoproteins than when associated with low-density lipoproteins tous'' [32]; the kinetics of drug absorption from adipose are [43] , and it is less toxic to mice with elevated levels of triglycernot known.
ides [44] . The clinical significance of changes in protein bindThe volume and speed of drug distribution are influenced ing by antimicrobials in obesity is unknown. by many factors, including mass, blood flow to tissues, protein and tissue binding, and kinetics of elimination of drug from tissue [33, 34] . The relative importance of each of these factors (oxidation, reduction, hydrolysis) are substrate-dependent and Tobramycin IBW / 0.58(ABW-IBW) [57] are usually increased or unchanged in obesity [8] . MetronidaFor children IBW / 0.40(ABW-IBW) [58] zole, clindamycin, erythromycin, and clarithromycin are meAmikacin IBW / 0.38(ABW-IBW) [59] tabolized by phase I reactions [50, 51] . In contrast, metabolism [61] of drugs by some phase II reactions (conjugation by sulfation Quinolone or glucuronidation) is consistently increased in obesity [8, 52] .
Ciprofloxacin IBW / 0.45(ABW-IBW) [62, 63] Zidovudine is metabolized by glucuronidation [53] . was used, the CrCl was underestimated [54] . Thus, Salazar † May vary for different sulfonamides.
and Corcoran proposed alternative formulas (based on animal models) for CrCl in obese subjects, to more accurately predict the elimination of drugs primarily excreted by glomerular filMiskowiak and colleagues looked at the absorption of oral penicillin before and after gastroplasty for morbid obesity in tration [24] . These equations require clinical confirmation.
Pharmacokinetics may be different in the extremely or morpatients initially weighing an average of 117 kg [70] . They found that absorption was not altered by obesity or by gasbidly obese (an ABW of §200% of IBW) than in the mildly or moderately obese [8] , but no comparative studies have been troplasty; serum levels were the same before and after the surgery and were within the recommended therapeutic range performed with regard to antibiotics.
In sum, although there are many potential pharmacokinetic for penicillin [70] . Kampmann and colleagues studied the pharmacokinetics of consequences of obesity, the actual consequences for the pharmacokinetics and clinical efficacy of antimicrobials in humans iv and oral ampicillin in patients who weighed an average of 131 kg before gastric bypass [71] . They found that the volume are largely unknown.
of distribution was 0.60 L/kg before surgery, compared with 0.41 L/kg in the same patients 1 year later, when the average weight was 87 kg. This suggests that ampicillin is distributed Individual Antibiotics (Table 3) in adipose tissue to some extent. They did not report the serum concentrations. b-Lactam drugs. In general, b-lactam drugs are proteinbound and hydrophilic and do not diffuse well into adipose.
Yuk et al. measured nafcillin serum levels in a patient with endocarditis who weighed 162 kg and concluded that there was The pharmacokinetics of b-lactam drugs in obesity have not been studied systematically; most of the data reviewed here a significant increase in the volume of distribution [72] . They suggested that a modified dosing regimen, such as 3 g every are derived from small studies or single case reports. Although an empirical DWCF of 0.30 can be suggested on the basis of 6 hours, was needed to achieve the same drug concentration as observed in nonobese patients receiving 2 g every 4 hours. the water composition of adipose, there are no clinical study data to confirm this approach. While b-lactam drugs are not Pories et al.
[73] studied the tissue levels of cefazolin following perioperative administration of prophylactic cefazolin in associated with concentration-dependent killing, a serum or tissue concentration below an MIC might lead to antibiotic obese patients weighing an average of 129 kg. They concluded that 1 g given iv 2 hours before surgery and again at induction failure.
/ 9c33$$jy29
06-13-97 19:28:00 cida UC: CID of anesthesia and 500 mg given every 6 hours for eight doses nation half-life) cancels out the effect of increased clearance, resulting in an elimination half-life that is similar for both yielded adequate tissue levels [73] . However, Forse and colleagues [74] found that a 1-g infusion in patients weighing an obese and lean subjects. As a consequence, alteration in dosage interval is not necessary for obese individuals. average of 127.3 kg yielded serum levels below the MICs for many surgically relevant bacteria. This study was the only one Human and animal data indicate that nephrotoxicity associated with aminoglycoside use is more common in obese subthat looked at the clinical outcome of adjusting the dose upward for obese patients. Surgical wound infection rates dropped from jects, perhaps because of an increased concentration of aminoglycoside in the kidneys [26, 60] . In one report, an increase 16.5% to 5.6% when the prophylactic dose of cefazolin was increased from 1 g to 2 g for obese patients.
was noted in the incidence of nephrotoxicity (as measured by a doubling of serum creatinine level) in mildly obese patients Mann and Buchwald studied the distribution and elimination of cefamandole during and after gastric bypass surgery in indi-(with body mass indices of 27 -29 kg/m 2 ), as compared with the incidence in control patients (whose body mass indices viduals weighing a mean of 230% of IBW [16] . They found that in their subjects the volume of distribution and clearance of were 19 -24 kg/m 2 ) [60] . More nephrotoxicity was observed in obese subjects despite the fact that their total aminoglycoside cefamandole were higher, and they concluded that the surgicalprophylaxis dosage of cefamandole should be 2 g at induction doses and duration of therapy were similar to those of the control subjects. Serum concentrations were maintained within of anesthesia and every 3 hours thereafter during prolonged procedures.
the recommended ranges. One confounding factor, however, was the greater likelihood of obese patients to have received Chiba et al. [17] studied the pharmacokinetics of cefotiam in sumo wrestlers weighing 130% -220% of IBW. They found furosemide.
Vancomycin. Although two studies [55, 81] concluded that that the volume of distribution was twice that for people weighing 100% of IBW. When kinetic parameters were advancomycin doses for obese patients should be based on ABW, only one of these studies analyzed patients receiving vancomyjusted on the basis of BSA, the differences in volume of distribution and clearance were not significant. They concluded that cin for therapeutic purposes [81] . Blouin et al. [55] studied six morbidly obese subjects and concluded that ABW should be the dose of cefotiam should be calculated on the basis of BSA for morbidly obese athletes.
used to determine vancomycin doses. Vance-Bryan and colleagues [81] studied vancomycin pharmacokinetics in 107 paYost and Derendorf found that the volume of distribution of cefotaxime, a very hydrophilic drug, increased by 50% and its tients weighing 20% or more over their IBWs and also concluded that using empirical dosage regimens such as 1 g every clearance increased by 25% in patients weighing 190% -210% of IBW [15] . Despite these changes, the authors did not believe 12 hours would produce suboptimal peak and trough vancomycin concentrations in the serum of obese patients. They recomthat it was necessary to adjust the dose of cefotaxime. Brown and Sands concluded that ceftriaxone should not be given in mended basing the dose on ABW and giving 20 -30 mg/kgrd [81] . Nonstandard doses should be checked by measuring a dosage of 1 g every 24 hours to morbidly obese patients, but they did not state the basis for this opinion [75] .
troughs and perhaps peaks.
Sulfonamides. Kaul and Ritschel demonstrated increased Aminoglycosides. Determining the daily dose of an aminoglycoside with use of ABW may result in higher than desirable numbers of free fatty acids and decreased protein binding of sulfonamides in genetically obese Zucker rats [28, 29] . In their serum concentrations, while doses based on IBW may lead to subtherapeutic serum concentrations [76] . These findings are studies, however, the volume of distribution for various sulfonamide antibiotics depended on many factors, not simply protein consistent with the fact that aminoglycosides are primarily distributed into extracellular fluid.
binding [28] . In a study of three patients before and after intestinal bypass surgery for morbid obesity, Garrett and colleagues Several small studies have determined DWCFs for aminoglycosides ranging from 0.38 to 0.58 [21, 57, 59, 76 -78] , [61] showed that the volume of distribution for iv and oral sulfisoxazole and its N 4 -acetylsulfisoxazole metabolite did not although Bauer et al. [76] found a wide range in DWCFs between individual patients. In these studies, obese patients change despite weight loss of as much as 44% of total body weight. Renal clearance of sulfisoxazole was essentially conweighed 125% -200% of IBW; were infected, presumed to be infected [21, 63] , or uninfected [57, 59, 77 -80] ; and were stant, but that of the N 4 -acetylsulfisoxazole metabolite decreased as total weight decreased. The investigators concluded given a single dose [78] or multiple doses of gentamicin [21, 76] , tobramycin [21, 76] , or amikacin [77] . Traynor et al. studthat the sulfisoxazole dose should not be determined on the basis of weight. ied 1,708 patients (weighing an average of 150% of IBW) and calculated a DWCF of 0.43 [21] . However, given the broad Quinolones. Ciprofloxacin is distributed less to adipose than to other tissues [62] , a circumstance suggesting that calcurange of DWCFs for individual patients [76] , final dosage adjustments should be based on serum concentrations. lating a dose on the basis of ABW would overestimate the dose. Allard and colleagues studied the volume of distribution Although the clearance of aminoglycosides in obese humans is significantly higher than in lean controls [76] , the larger for ciprofloxacin and found that it was 23% greater in obese subjects weighing an average of 160% of their IBW than in volume of distribution in obese subjects (which prolongs elimi-/ 9c33$$jy29 06-13-97 19:28:00 cida UC: CID nonobese controls [62] . They also determined that ciprofloxacin the treatment of candidemia, Rex et al. specified that patients being treated with fluconazole and weighing ú90 kg received clearance was increased. They found that maximum ciprofloxacin plasma concentrations were lower in obese subjects than 6 mg/kg [67] . No rationale was given for that dose. Antivirals. A study in which a single dose of acyclovir was in nonobese ones after a 400-mg iv infusion, but the concentrations were still within the recommended therapeutic range.
administered to seven uninfected subjects weighing an average of 203% of IBW demonstrated that pharmacokinetic parameAllard et al. [62] concluded that the ciprofloxacin dose should be based on IBW plus a DWCF of 0.45.
ters were not significantly different from those in a normalweight control group; the authors concluded that doses should Caldwell and Nilsen [63] described a patient weighing 250 kg who had an infection requiring iv ciprofloxacin. They be based on IBW [68] . Acosta and colleagues [69] found that ''standard doses'' of zidovudine (200 mg and 100 mg, respecused the formula of Allard et al. [62] and measured peak serum ciprofloxacin level 20 minutes after completion of a 60-minute tively) yielded lower-than-expected plasma concentrations in two women weighing 142.5 kg and 128 kg; the conclusion infusion on day 4 of therapy; the level was 4.2 mg/L, within the recommended therapeutic range of 0.5 -5.0 mg/L.
with regard to dosing in obesity is complicated by the fact that the women were pregnant. Macrolides. Little has been written about macrolide dosing in obesity. Prince and colleagues administered 250 mg of oral erythromycin base to seven obese adults, weighing an average Children of 157.7 kg, prior to bariatric surgery [64] . This dose resulted in a mean peak concentration of 1.04 mg/mL, a peak concentration Antibiotic dosage is routinely calculated on the basis of weight for children, although some authors believe that BSA similar to that in nonobese adults [82] .
Mycobacterial antibiotics. In a single case report of a subis more appropriate [20] . Should IBW (table 2) [12] or ABW be used for obese children? For children, the difference between ject weighing 190% of his IBW, Geiseler et al. noted that dosing rifampin, streptomycin, ethambutol, and pyrazinamide IBW and ABW is usually relatively small [83] . Dudley concluded that IBW is probably appropriate for most situations on the basis of IBW yielded levels in the therapeutic range [65] . Isoniazid levels were not measured.
[83]. Koshida et al. studied the volume of distribution for tobraAntifungals. Amphotericin is a highly lipophilic drug and has traditionally been dosed on a weight basis, with doses mycin and cefazolin in a group of children with an average ABW of 161% of IBW, and they concluded that the loading ranging from 0.5 to 1.5 mg/kg, depending on the severity of the infection. There is a single case report of an obese patient dose of cefazolin should be calculated on the basis of ABW, while the initial tobramycin dose should be calculated on the with nonmeningeal cryptococcal infection successfully treated with amphotericin B plus flucytosine, followed by oral flucobasis of the IBW plus a DWCF of 0.40(ABW -IBW) [58] . nazole [66] . The dose of amphotericin was based on ABW; levels were not determined. The dose of flucytosine was based
Surgical Prophylaxis
on IBW, and serum levels were maintained within the desired therapeutic range, without hematologic toxicity.
Numerous studies have identified obesity as a factor in postoperative wound infections; this is usually attributed to meKoldin and colleagues [30] , using a rabbit model made hypercholesterolemic by diet, found that there was no difference chanical complications, but it is possible that antibiotics do not achieve effective levels in obese patients [16, 74] . Pories et al. in the level of amphotericin B toxicity in comparison with that in normal rabbits. When amphotericin B was given in a mixture [73] concluded that 1 g of prophylactic cefazolin given 2 hours preoperatively and again at induction of anesthesia to morbidly with human low-density lipoproteins, it was more toxic than when given without the lipoproteins, but this level of toxicity obese patients before gastric bypass surgery yielded adequate antibiotic concentrations in tissue, but Forse et al. [74] sugwas not compared with that in rabbits given human lipoproteins alone.
gested a dose of 2 g iv (instead of 1 g iv or im) at induction of anesthesia [73]. Vadiei et al. [27] found that volume of distribution and clearance of amphotericin B were markedly decreased and renal Mann and Buchwald studied cefamandole levels in serum, adipose tissue, and wound drainage during and after surgery toxicity increased in obese Zucker rats with hyperlipoproteinemia as compared with those in lean litter mates; they attributed in morbidly obese patients and concluded that the surgicalprophylaxis dose of cefamandole should be 2 g at induction this to lipoprotein binding of amphotericin B in the vascular space. Chavanet et al. found that an increase in serum triglycerof anesthesia and every 3 hours thereafter during prolonged procedures [16] . ides -but not cholesterol in very-low-density and low-density lipoproteins -resulted in decreased renal toxicity in a mouse model [44] . The net clinical consequence of these observations Conclusions is unclear.
There is less experience with the pharmacokinetics of azoles. With the exception of the aminoglycosides, the net effect of the pharmacokinetic consequences of obesity has not been In a recent article comparing amphotericin and fluconazole for / 9c33$$jy29 06-13-97 19:28:00 cida UC: CID
